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Abstract: Gastric cancer (GC) is turning out today to be one of the most important welfare issues
for both Asian and European countries. Indeed, while the vast majority of the disease burden is
located in China and in Pacific and East Asia, GC in European countries still account for about
100,000 deaths per year. With this review article, we aim to focus the attention on one of the
most complex cellular pathways involved in GC proliferation, invasion, migration, and metastasis:
the MAP kinases. Such large kinases family is to date constantly studied, since their discovery more
than 30 years ago, due to the important role that it plays in the regulation of physiological and
pathological processes. Interactions with other cellular proteins as well as miRNAs and lncRNAs
may modulate their expression influencing the cellular biological features. Here, we summarize the
most important and recent studies involving MAPK in GC. At the same time, we need to underly
that, differently from cancers arising from other tissues, where MAPK pathways seems to be a gold
target for anticancer therapies, GC seems to be unique in any aspect. Our aim is to review the current
knowledge in MAPK pathways alterations leading to GC, including H. pylori MAPK-triggering to
derail from gastric normal epithelium to GC and to encourage researches involved in MAPK signal
transduction, that seems to definitely sustain GC development.
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1. Introduction
Every cell in our body is capable to respond to external stimuli such as growth factors, inflammation,
cytokines, microenvironmental changes, and to interact with other cells, owing to a complex molecular
mechanism based on the action of the mitogen-activated protein kinases (MAPKs). MAPKs are
a large family of serine/threonine kinases that, upon the reception of a stimuli, trigger a cascade of
phosphorylation leading to a precise and specific cellular response. Commonly the canonical pathway
starts with the MAPKKKs, among which Raf isoforms are the better known and the most described in
the scientific literature [1], that phosphorylate and activate the MAPKKs. To this family belongs the
MAPK/ERK kinase (MEK) which plays a fundamental role in the activation of ERK1/2, which are the
first mammalian MAPK genes to be identified in the late 1990s [2]. Even though ERK1/2 are the most
studied members of the MAPKs family, many other are described to be involved in cancer development
such as ERK3, ERK4, ERK5, and ERK7/8 [3,4]. MAPK pathway can be dysregulated in many ways
in gastric cancer (GC), their components being in turn affected by trans-regulating components such
as drugs, ligands, or endogenous proteins indirectly related to the pathway, or directly, because of
mutations occurring in the components of the pathway itself. Noteworthy, important MAPKKK
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such as RAF and its binding factor RAS are often mutated in gastrointestinal tumors [5,6]. Moreover,
the picture is further complicated since non-coding RNA popped up. In particular, micro RNAs
(miRNAs) and long non coding RNAs (lncRNAs) have been discovered to intervene in regulating the
MAPK pathway at different levels [7,8]. The regulation of such a complex mechanism is fundamental
in tumorigenesis and metastasis. Indeed, many types of cancers present a dysregulated MAPKs system,
altering many cellular properties such as metabolism, cell proliferation, apoptosis, and migration [9].
2. The Gastric Cancer Biological Complexity
GC which is actually the fifth most frequently diagnosed cancer and the third leading cause of
cancer death according to GLOBOCAN 2018 [10], demonstrated in the past two decades a high rate
of metastasis particularly localized in the liver (48% of metastatic GC patients), peritoneum (32%),
lung (15%), and bone (12%) [11]. Metastasis formation, which is a very complex biological mechanism
with hundreds of proteins involved, is reported to be regulated not only by focal adhesion on the
cell membrane but also by matrix metalloproteinases (MMPs), which in turn are able to degrade
the extracellular matrix allowing the intravasation of cancer cells into the endothelial or lymphatic
vessels [12]. Currently, one of the few targeted therapies available for advanced GC is the use of
Trastuzumab [13] combined with fluoropyrimidine plus cisplatin, when the amplification of the HER2
gene is revealed by liquid or solid biopsy. Indeed, HER2 is another important oncogene that is
able to promote invasion and metastasis by stimulating selectively the RAF/ERK pathway and thus
activating oncogene such as c-Fos, elk1, and c-Myc [14]. The majority of GC are adenocarcinomas
which can be classified by different criteria. Among these, the Lauren histopathology system, which is
still widely used, distinguishes two principal subtypes: namely, the intestinal and diffuse subtypes.
Tumors that do not fit these types are considered mixed and indeterminate subtypes [15]. This
classification is also epidemiologically relevant. Indeed, intestinal GC, which is more common in
elderly patients, mainly males, is more often associated with intestinal metaplasia and Helicobacter
pylori infection, and metastasize mainly to the liver through blood flood. Diffuse GC most commonly
occurs in young patients, mainly females, presents a hereditary component and metastasize through
peritoneal surfaces. Moreover, the diagnosis of diffuse GC is a pejorative prognostic factor, since it
behaves more aggressively than intestinal GC. The extraordinary molecular heterogeneity of GC that
has been highlighted by studies on somatic copy number alterations, gene mutations, epigenetic,
and transcriptional changes etc., [16], led to a new classification. In 2014, the milestone study carried out
by the Cancer Genome Atlas (TCGA) research network created a molecular-based stratification method
that classifies GCs in four groups: 1) Epstein-Barr virus-positive GCs with high DNA hypermethylation,
frequent JAK2 and PD-L1 amplification and PIK3CA mutations; 2) microsatellite unstable GCs with
DNA hypermethylation and MLH1 silencing; 3) genomically stable GCs with frequent CDH1 and
RHOA mutations and correlated with diffuse morphology; 4) chromosomally unstable GCs with
high TP53 mutations, tyrosine kinase receptors amplification and intestinal morphology. To better
understand the dichotomy of the GC classification, we reported in Figure 1 the comparison between the
classical Lauren histopathology system and the new molecular one. Consistent with elevated genetic
instability, mutations found in GCs are extremely divergent and have no characteristic driver gene
mutations. Moreover, it was reported that genes involved in the Ras/ERK signaling pathway, such as
FGFR2, KRAS, EGFR, ERBB2, and MET, are amplified in a mutually exclusive manner in approximately
40% of GC cases [17]. In spite of the increasing knowledge of molecular biology of GC, surgical
resection of cancer and extended lymph node dissection remain the only effective curative therapy for
GC, as in 70–90% of cases, owing to chemoresistance, chemotherapy is unable to inhibit the tumor
growth, invasiveness, and metastasis spread [18]. Here we focus on the most recent advancements in
the dysregulation of the MAPK pathway in GC.
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Figure 1. After tumor resection via surgery, the biopsy is processed through immunohistochemical 
(IHC) protocols, leading to a classical Lauren histopathological classification and/or exploiting in situ 
hybridization (ISH) techniques to evaluate EBV positivity (EBV), microsatellites instability (MSI), 
chromosomal instability (CIN), and genomical stability (GS). 
3. The ERK/MAPK Pathway in Gastric Cancer 
In recent years, ERK-MAPK relationships have been abundantly studied, since mutations and/or 
alterations of activation pathways has been associated with neoplastic phenotypes of a large number 
of human tumor cells [19]. Various studies have demonstrated that the ERK/MAPK pathways are 
involved in the regulation of cell motility both in GC and in normal epithelia. Indeed, ERK regulates 
the activity of MMPs in GC, thus influencing cell migration and invasiveness [20]. Moreover, the 
secreted protein angiopoietin-like-4 (ANGPTL4), which is induced by hypoxia, exerts various effects 
on the neoplastic progression in scirrhous gastric carcinoma. GC cells may acquire resistance to 
anoikis through the activation of ANGPTL4-mediated FAK/Src/PI3K-Akt/ERK signaling, inducing 
the development of peritoneal metastases [21]. There are various studies that have correlated the 
alteration of the ERK/MEK pathway with the processes of invasion and metastasis; such processes 
involve motility and cell adhesion and epidermal growth factor receptor (EGFR)-induced 
disassembly of focal adhesions which is regulated by activating the ERK/MAPK pathways [22]. The 
p38 pathway turns out to be deregulated in many cancers as well. p38 signaling is involved in the 
regulation of the epithelial-to-mesenchymal transition (EMT) and in the production of reactive 
oxygen species (ROS) triggered by EMT which are significantly generated in GCs. One of the targets 
activated by ROS is EGFR whose overexpression has been linked to lymph node diffusion and 
consequently to a worse prognosis in GC. These studies have demonstrated the involvement of the 
EGFR/Ras/MAPK signaling pathway in the activation of NF-κB, in the induction of the 
cyclooxygenase-2 (COX-2) and in the proliferation of GC cells. NF-κB stimulates the transcription of 
COX-2, a regulator of cell proliferation. Upregulation of COX-2 facilitates the development of cancer 
and reduces apoptosis. High levels of COX-2 protein and mRNA have been detected in tissues of 
patients with GC. It is evident how the EGFR/Ras/MAPK signaling pathway is involved in the 
activation of NF-κB, through COX-2 induction, and in the stimulation of GC cells proliferation. Han 
et al. found that lycopene inhibits cell proliferation and induces cell apoptosis by reducing the levels 
of ROS, and thereby inhibiting ROS-activated EGFR/Ras/ERK and p38 MAPK signaling pathways 
and suppressing NF-κB p50/p50-mediated COX-2 gene expression in the Caucasian GC cell lines AGS 
Figure 1. After tumor resection via surgery, the biopsy is processed through immunohistochemical
(IHC) protocols, leading to a classical Lauren histopathological classification and/or exploiting in
situ hybridization (ISH) techniques to evaluate EBV positivity (EBV), microsatellites instability (MSI),
chromosomal instability (CIN), and genomical stability (GS).
3. The ERK/MAPK Pathway in Gastric Cancer
In recent years, ERK-MAPK relationships have been abundantly studied, since mutations and/or
alterations of a tivation pathways has been associated with neoplastic phenotypes of a large number of
human tumor cells [19]. Various studies have demonstrated that the ERK/MAPK pathw ys are involved
in the regulation of cell motility both in GC and in normal epithelia. Indeed, ERK regulates the activity
of MMPs in GC, thus influencing cell migration and invasiveness [20]. Moreover, the secreted protein
angiopoietin-like-4 (ANGPTL4), which is induced by hypoxia, exerts various effects on the neoplastic
progression in scirrhous gastric carcinoma. GC cells may acquire resistance to anoikis through the
activation of ANGPTL4-mediated FAK/Src/PI3K-Akt/ERK signaling, inducing the development of
peritoneal metastases [21]. There are various studies that have correlated the alteration of the ERK/MEK
pathway with the processes of invasion and metastasis; such processes involve motility and cell
adhes on and epidermal growth factor receptor (EGFR)-induced dis ssembly of focal adhesions which
is regulated by activating the ERK/MAPK pathways [22]. The p38 pathway turns out to be deregulated
in many cancers as well. p38 signaling is involved in the regulation of the epithelial-to-mesenchymal
transition (EMT) and in the production of reactive oxygen species (ROS) triggered by EMT which are
significantly generated in GCs. One of the targets activated by ROS is EGFR whose overexpression has
been linked to lymph node diffusion and consequently to a worse prognosis in GC. These studies have
demonstrated the involvement of the EGFR/Ras/MAPK signaling pathway in the activation of NF-κB,
in the induction of the cyclooxygenase-2 (COX-2) and in the proliferation of GC cells. NF-κB stimulates
the transcription of COX-2, a egul or of cell proliferation. Upregulation of COX-2 facilitat s the
development of c ncer and reduc s ap ptosis. High levels of COX-2 prot in and mRNA have been
detected i tissues of patients with GC. It is evident how the EGFR/Ras/MAPK signaling pathway
is involved in the activation of NF-κB, through COX-2 induction, and in the stimulation of GC cells
proliferation. Han et al. found that lycopene inhibits cell proliferation and induces cell apoptosis
by reducing the levels of ROS, and thereby inhibiting ROS-activated EGFR/Ras/ERK and p38 MAPK
signaling pathways and suppressing NF-κB p50/p50-mediated COX-2 gene expression in the Caucasian
GC cell lines AGS [23]. On the other hand, a large number of studies on GC have shown that the MAPK
pathway is associated with apoptosis and autophagy [24]. Liu et al. used ginsenoside Rg5, a rare
saponin belonging to the protopanaxadiol ginsenoside family, used as a therapy against many types
of cancers, in order to demonstrate its anticancer effect also in GC [25]. In this case Rg5 led to a ROS
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increase and activated the MAPK pathways, such as those involving p38 and JNK, that works as cancer
suppressor, promoting apoptosis autophagy and blocking the cell cycle during the G2/M transition.
Also, ERK activation contributed to ROS-associated Rg5-induced GC death. Finally, it was reported
the special AT-rich sequence-binding protein 2 (SATB2) as a new tumor-suppressive gene playing an
important role in many cancers, including GC. Downregulation of SATB2 in patients with GC was
associated with shortened survival and, in the gastric cancer cell line MGC-803, the overexpression of
SATB2 was able to repress ERK5 expression, while activation of ERK5 restored the SATB2-induced
inhibition of proliferation and migration [26,27]. Even though we reported few examples of the
relationships between metastasis formation and the abnormal activation of MAPKs in GC, describing
the complex interconnection leading to anoikis resistance, cell adhesion loosening, MMPs secretion
and activation, increased proliferation and migration, many efforts need to be still spent in order to
elucidate every single pathway and thus uncover new possible targets for future therapies. The main
pathways reported above were summarized in Figure 2.
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Figure 2. Although several kinases pathways are deregulated in GC, we reported here three ways by 
which ERK1/2, PI3K/Akt, p38, and ERK5 are activated. Hypoxic condition may trigger, through the 
ANGPTL4/FAK/Src/ERK1/2 – PI3K/Akt axis, events aimed to increase GC cells metastatic potential, 
such as induction of anoikis resistance, MMPs secretion, loosening of cell adhesion; ROS, influencing 
EGFR and p38, are able to activate NF-kB translocation into the nucleus leading to the transcription 
of COX-2 gene; SATB2, which is commonly downregulated in poor prognosis GC patients, being able 
to inhibit ERK5, is capable to decrease cell proliferation and migration, acting as a tumor suppressor 
transcription factor. 
4. Pharmaceutical Effects of MAPK Targeting in Gastric Cancer 
Many studies reported a correlation between the efficacy of antiblastic drugs and the blockage 
of ERK1/2 activation. Indeed, the MAPK/ERK Kinase is deregulated in one-third of all human 
cancers. It is estimated that approximately 37% of patients with GC are potentially targetable by 
RTK/RAS-directed therapies [28]. Signaling pathway inhibitors are recognized to be effective and 
there are currently several clinical trials ongoing. For GC multiple classes of antibiotics were found 
to inhibit the ERK/MAPK pathway. A recent study repurposed 26 antimicrobials agents which were 
screened on AGS GC cell line for their potential to target the ERK/MAPK pathway [29]. Among these, 
the most effective was doxycycline, a widely used antibiotic, that acts by interrupting the tRNA 
binding to the 30S ribosomal subunit during translation. Doxycycline is involved in various processes 
Figure 2. Although several kinases pathways are deregulated in GC, we reported here three ways
by which ERK1/2, PI3K/Akt, p38, and ERK5 are activated. Hypoxic condition may trigger, through
the ANGPTL4/FAK/Src/ERK1/2–PI3K/Akt axis, events aimed to increase GC cells metastatic potential,
such as induction of anoikis resistance, MMPs secretion, loosening of cell adhesion; ROS, influencing
EGFR and p38, are able to activate NF-kB translocation into the nucleus leading to the transcription of
COX-2 gene; SATB2, which is commonly downregulated in poor prognosis GC patients, being able
to inhibit ERK5, is capable to decrease cell proliferation and migration, acting as a tumor suppressor
transcription factor.
4. Pharmaceutical Effects of MAPK Targeting in Gastric Cancer
Many studies reported a correlation betwe n the effi f antiblastic drugs and the blockage
of ERK1/2 activ tion. I deed, the MAPK/ERK i i eregulated in one-third of all human
cancers. It is estimated that pproximately 37% of ti ts ith GC are potentially targeta le by
RTK/RAS-directed therapies [28]. Signaling pathway inhibitors are recognized to be effective and there
are currently several clinical trials ongoing. For GC multiple classes of antibiotics were found to inhibit
the ERK/MAPK pathway. A recent study repurposed 26 antimicrobials agents which were screened on
AGS GC cell line for their potential to target the ERK/MAPK pathway [29]. Among these, the most
effective was doxycycline, a widely used antibiotic, that acts by interrupting the tRNA binding to
the 30S ribosomal subunit during translation. Doxycycline is involved in various processes such as
induction of apoptosis, reversion of EMT by restoring the expression of E-Cadherin, blockade of the
cycle in G1-S, stabilization of p53 and p21, regulation of cell adhesion and migration, modulation
of the ROS/ASK1/JNK pathway. Pandian and colleagues have shown on AGS, MKN45, and KATO
III GC cells that doxycycline inhibited ERK/MAP pathway, both at transcriptional and protein level.
In such a way, doxycycline blocked proliferation, colony formation, the ability to form spheroids and
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also inhibited a factor, the HSP90, which triggered the upstream cascade. The pathways inhibited by
doxycycline, such as the ERK/MAPK, ER, E2F, Myc, Wnt, Notch, SMAD2/3/4, and OCT4, are largely
expressed in a specific subset of GCs, which justifies the repurposing of this drug Another well-known
inhibitor is Metformin, which is a biguanide drug that is used in the treatment of type II diabetes
and epidemiological studies have suggested that its use is associated with a decreased incidence of
various types of cancer [30]. It has been reported to inhibit cell proliferation in human GC cell lines,
including MKN45, MKN47, MKN-28, SGC-7901, and BGC-823 and reduce metastasis of human AGS
cells, by inhibiting EMT in a glucose-independent manner [31]. A recent study shows how metformin
inhibited viability and promoted apoptosis in AGS GC cells [32]. Metformin-induced apoptosis may
be mediated via downregulation of ERK, JNK, and p38 phosphorylation. By decreasing insulinemia
and glycemia, metformin can block the PI3K/MAPKs signaling pathway, which are implicated in
cancer cell growth. Many natural products isolated from animals, plants, fungi, and bacteria are
used for the treatment of various diseases, including cancer. Quercetin is a flavonoid identified in
vegetables, fruits, and tea which inhibits p38, ERK, and JNK committing to death of AGS cells [33].
Li and Chen analyzed the effect of Quercetin on GC metastasis and the correlation of its effect with
the uPA/uPAR system. The uPA/uPAR system is known to be critically important in GC metastasis
development and high levels of uPA and uPAR may predict an adverse outcome in GC patients. In this
study, Quercetin has demonstrated its antimetastatic effects on GC by blocking uPA/uPAR-dependent
pathways. The suppression of the uPA/uPAR exercised by Quercetin may be related to NF-κb, PKC-δ,
and ERK1/2 inhibition. Indeed, the latter is an important regulator, since its inhibition was associated
with a reduced expression of uPA and uPAR. Fisetin is another flavonoid found in fruit and vegetables
that has proven to exert an inhibitory effect on the proliferation of SGC7901 cells and induced apoptosis
through suppression of ERK1/2 activation [34]. Another recent study has shown how Parameritannin
A2, a product extracted from the stems of the plant Urceola huaitingii, has a synergistic effect with
doxorubicin in GC cells. Doxorubicin is widely used as an antiblastic but induces chemoresistance
and has cardiotoxic effects. Following treatment with doxorubicin, the PI3K/Akt, ERK1/2 and p38
signaling pathways were all activated but the synergistic treatment with Parameritannin A2 increased
doxorubicin-induced mitochondria-dependent apoptosis [35]. Although many promising preclinical
drugs are under development, currently only few clinical trials are ongoing on MAPKs targeting
agents. Among the phase I concluded studied, we report the Triptolide, a compound extracted from
the Tripterygium wilfordii, a Chinese medicinal plant, which effect is mediated by the suppression of
oncoproteins, including DUSP1 [36], NF-κB, and heat shock proteins [37].
5. SPON2 and RAB13 as Two Novel MAPK Regulators in Gastric Cancer
SPON2, which is the secreting-type ECM Spondin 2 (SPON2, formerly Mindin, DIL-1), a member
of the Mindin F-Spondin family, is highly expressed in many tumors but its molecular mechanisms
and implication in cancer remains unclear although high levels of expression are correlated with a poor
prognosis, migration, and proliferation [38]. SPON 2 levels are higher in metastatic GCs and SPON2
serum levels are higher in patients compared to healthy controls as well, and such levels increase as
disease progresses. SPON2 promotes the EMT of malignant cells through the ERK1/2 pathway and
the activation of signaling pathways such as the MAPK cascade, which contributes to relapse and
metastasization of GC. p-ERK1/2 has been significantly reduced in SPON2 knockdown cells, although
the levels of ERK1/2, p-MAPK8, MAPK14, MAPK8, and p-MAPK14 were not significantly different.
Low SPON 2 levels inhibit EMT in GC deregulating ERK1/2 pathways and consequently affecting
migration and invasion. Another non-canonical ERK1/2 regulator, RAB13, which is a member of the
Rab GTPase family, is located in specific organelle membranes and vesicles, and cooperates to strictly
regulate each step of the membrane traffic. Chen et al. examined the biological function of RAB13 in
AGS GC cells and demonstrated that depletion of RAB13 attenuated the activation of Akt/ERK/mTOR
signaling pathways through the inhibition of the expression level of EGFR in the plasma membrane [39].
All the three phosphorylated proteins are nodal in the signaling pathways supporting survival, growth,
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and proliferation in GC, and decreased levels of these proteins demonstrated that cells viability was
hampered. This, at least partially, explains why RAB13 stimulates growth and proliferation via
activating Akt, mTOR, and ERK pathways in GC cells.
6. Helicobacter Pylori: The Great Exploiter of MAPKs
GC is a multifactorial disease, whose risk factors are represented by complex interplays among
pathogen, environmental and host-related factors [40]. Among pathogens, it is widely accepted that H.
pylori infection plays a major etiological role in the development of GC, accounting up to 89% of the
disease [41]. Since 1994, a three-cohort study led the WHO International Agency for Research on Cancer
to classify H. pylori as a group 1 carcinogen [42]. Helicobacter pylori is a Gram-negative bacterium that is
able to persistently colonize the human gastric mucosa, being fitted with enzymes and virulence factors
allowing it to outlive the extreme conditions proper of the stomach [43]. First, on the eve of surviving,
ingested H. pylori buffers unfavorable gastric lumen low pH through the secretion of the enzyme urease
that converts urea into ammonia and bicarbonate. Subsequently, H. pylori uses its unipolar flagella
to move across the thick mucus layer until it reaches the gastric surface. Owing to the triggering of
immunosuppressive mechanisms, if not eradicated by antibiotic treatment, H. pylori colonization of
gastric surface may become chronic, inducing an equally chronic inflammation state increasing cell
turnover that, over time, can lead to the destruction of normal gastric glands (gastric atrophy) and
their replacement with intestinal-type epithelium (intestinal metaplasia), being atrophic gastritis and
intestinal metaplasia precancerous lesions that can progress to GC [44]. It is a matter of fact that host-H.
pylori interactions are mainly mediated by virulence factors that trigger or alter MAPK signaling of
host cells, to regulate proliferation of gastric epithelial cells [45], to escape immunosurveillance, and to
generate a chronic inflammatory state. CagA (cytotoxin-associated bacterial protein A) is a 120-140
kDa unique protein, encoded by the cagA gene, which belongs to the cag pathogenicity island (cagPAI),
together with other genes coding for proteins that assemble to form a type IV secretory system (T4SS) to
export proteins outside the bacterium [46]. cagPAI is only found in highly virulent strains, with a rate
between 90–95% in East Asian countries, and about 40% in Western countries [17]. CagA is considered
a true oncoprotein, as its presence is associated with the appearance of precancerous lesions and
a higher risk of developing GC [47]. Following the adhesion of the bacterium to the surface of the cell
of gastric epithelium, the T4SS, acting like a syringe, delivers CagA inside the cytoplasm of the host
cell. CagA, localized to the inner face of plasma membrane, induces hypermobility and morphological
changes in the epithelial cell, that assumes the so-called “hummingbird phenotype,” which recalls that
of cells that are treated with some growth factors. Indeed, when phosphorylated in apposite domains
by host tyrosine kinases, like c-src and c-abl, CagA acts an impostor to recruit the SH2-containing
domain SHP2 protein, a tyrosine phosphatase needed to fully activate the Ras/ERK MAPK pathway [48].
Tyr-phosphorylated-CagA lures SHP2, mimicking SHP2-recruitment by phospho-Tyr exposed by
ligand-activated tyrosine kinase receptors (RTKs). This leads to an alteration of intracellular signaling,
resulting in an increase of the proliferation rate of gastric epithelium cells, through a sustained
activation of the Ras/ERK MAPK pathway [49]. Furthermore, Ras/ERK MAPK pathway can be directly
activated by this viral factor in a phosphorylation-independent state. CagA can interact with an
adaptor protein like GRB2, thus allowing recruitment of SOS, the RAS GTPase exchange factor, to the
plasma membrane, thus stimulating cell proliferation and scattering [50]. The increase in the mutation
rate because of hyperproliferation, together with a state of chronic inflammation, is consistent with
the definition of tumorigenesis as a “wound that never heals.” Indeed, it is well-known that H. pylori
infection induces the production of potent pro-inflammatory cytokines by different cell types [51].
Whole genome profiling of H. pylori-exposed gastric epithelial cells revealed that interleukin-8 (IL-8) is
the most markedly up-regulated gene [52]. This cytokine, initially characterized as a potent recruiter
and activator of neutrophils, later revealed to be a multifunctional factor, increasing angiogenesis,
EMT, extracellular matrix remodeling, and macrophage activation in physiological conditions [53].
According to the notion that most gastric carcinomas are the end product of a chronic inflammatory
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state, the strong upregulation of IL-8 due to the exposure of H. pylori, supports a chronic inflammatory
microenvironment that can eventually degenerate into a cancerous lesion [53]. Indeed, high levels of
IL-8 in gastric mucosa indicate an increased risk of developing GC, and plasmatic level of IL-8 can be
considered a diagnostic marker of this tumor [54]. H. pylori CagA induces epithelial gastric cells to
produce high levels of IL-8 even at a low bacterial load infection [55]. Again, signal transduction to
activate IL-8 gene expression occurs through the activation of ERK-MAPK pathway mediated by CagA.
The promoter region of the IL-8 gene contains binding sites for transcription factors, such as NF-κb,
and AP-1. CagA induces AP-1 by activating Ras/Raf/ERK MAPK pathway, both by P-CagA/SHP2-
and CagA/Grb2-dependent pathways. At the same time, phosphorylated ERK activates NF-κb that
translocate from cytosol to the nucleus to further activate IL-8 gene expression [56]. H. pylori can
upregulate IL-8 levels also by the activation of p38 MAPK, but through a different mechanism; rather
than inducing NF-κb translocation, p38 MAPK signaling induces the expression of p60 and p55 subunits
that form the dimer of NF-κb [57]. Although H. pylori is highly immunogenic, the host fails to eradicate
the infection in the majority of cases. This is partly due to the fact that this bacterium uses strategies
to escape eradication through the modulation of the effector functions of the cells of the immune
response, among which activated macrophages at the sub-mucosal space play a main role. JHP0290
and HP1286 are two poorly characterized proteins that are part of H. pylori secretoma. It has been
demonstrated that these proteins are virulence factors able to bind to and induce macrophage apoptosis,
through the ERK MAPK signal transduction pathway activation [58,59]. Furthermore, JHP0290 induces
ERK MAPK-dependent production of TNF-alpha [58]. This is an acid-suppressive, pro-inflammatory
cytokine. Together, these virulence factors contribute to create a favorable microenvironment, in which
the bacterium can escape the action of macrophages, lower acidity, and support the host’s inflammatory
response. About the involvement of H. pylori infection in gastric cancer progression, it was shown
that this bacterium induces up-regulation of the expression of VEGF, the main pro-angiogenic factor,
through the activation of p38 MAPK pathway in H. pylori-infected gastric cancer MKN45 cells [60].
All together such observations, summarized and represented in Figure 3, lead to define H. pylori as
a risk for GC development, influencing deeply not only the proliferative status of the gastric epithelia
but also inducing chronic inflammation and lowering the stomach pH.
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load infection [55]. Again, signal transduction to activate IL-8 gene expression occurs through the 
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MAPK signal transduction pathway activation [58,59]. Furthermore, JHP0290 induces ERK MAPK-
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response. About the involvement of H. pylori infection in gastric cancer progression, it was shown 
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risk for GC development, influencing deeply not only the proliferative status of the gastric epithelia 
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Figure 3. H. pylori may act as an oncogenic factor through several pathways and via many secreted 
proteins. In the above reported example, it is able to induce a chronic inflammatory status through 
the internalization of the CagA protein by gastric epithelial cells, which in turn triggers the 
Figure 3. H. pylori may act as an oncogenic factor through several pathways and via many secreted
proteins. In the above reported example, it is able to induce a chronic infla matory status through the
internalization of the CagA protein by gastric epithelial cells, which in turn triggers the up egulation of
IL-8 via Ras/Raf/ERK or p38 pathway; such protein might also stimulate the Ras GTPase SOS, to induce
cell proliferation. The secreted protein JHP0290 is able to induce TNFα transcription, mediated by ERK
activation, leading to immunosurveillance escape.
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7. MKK4 Involvement in Gastric Cancer Pathogenesis
MKK4 (also known as MEK4, SEK1, JNKK1, SKK1) is codified by the gene MAP2K4 located
on chromosome 17p11.2 and is involved in several complicated signaling networks and might play
different biological functions in different pathways, like cell proliferation and differentiation [61].
MKK4 has also been implicated in apoptosis and neoplastic transformation. The conflicting biological
effects of MKK4 in human cancer might reflect the complexity of MAPK signal transduction. Genetic
inactivation of the MKK4 gene on chromosome 17p has been reported in pancreatic, biliary, and breast
carcinomas [62]. Furthermore, progressive loss of MKK4 expression has been reported in prostate,
and breast cancers [63,64]. pMKK4 might function as a tumor suppressor in colorectal cancer.
Downregulation of pMKK4 was associated with a more aggressive phenotype and with increases in
local invasion and metastasis [65]. With regards to GC, MKK4 is mainly a tumor suppressor. Liang et al.
show that curcumin inhibited cell proliferation and caused BGC-823 cells apoptosis via ROS-mediated
ASK1-MKK4-JNK signaling pathways, but the activation of ASK1/MKK4/JNK cascade was effectively
inhibited by the ROS scavenger N-acetylcysteine (NAC), indicating that the production of ROS in
BGC-823 cells resulted in the signaling pathway activation [66]. A Chinese study correlated the impact
of genetic variation on the general FAS signaling pathway with GC risk [67]. The genes examined in
this pathway encode proteins involved in FAS receptor-ligand binding, initiator and effector caspases
and structural proteins. They found genetic variations that contribute significantly to the overall risk
of GC. Among these, MAP2K4 gene is significantly associated with GC. Polymorphisms in this gene
have been correlated with risk association in a number of cancers in both Chinese and Caucasian
populations, although several genetic discordances were highlighted between these two ethnicities.
8. Epigenetic Regulation via MAPK
Evidences suggest that ERK pathway is correlated with neoplastic progression, but the exact
epigenetic regulation mechanism to date is not clear. It is important to point out that post-transcriptional
modifications of the histones N-terminal can regulate chromatin organization and DNA utilization
processes, including transcription. Studies in which histone modification has been correlated with
tumorigenesis reported that deacetylases expression might be an independent prognostic marker in
GC [68,69]. Eukaryotic DNA is surrounded by an octamer made up of four different types of histones,
H2A, H2B, H3, and H4. H2A.X is the histone H2A family variant, and its phosphorylation at the site
Tyr-142 can participates in multiple biological processes, including DNA repair. Numerous studies
indicate that histone modifications are found in a high number of tumors and is considered very
important in GC [69]. A recent study has shown that Ras-ERK signal pathway decreased H2A.XY142ph
and promoted cell growth and metastasis, enhanced cell viability, cell colonies, and cell migration,
explaining how Ras-ERK pathway could promote GC cell growth [70]. Another study highlighted that
the activation of ERK1/2 signaling, induced by Ras mutation, might repress the phosphorylation of
H1.4 at Ser27, blocking its protecting activity [71], elucidating the impact on the link between H1.4
Ras/ERK1/2-mediated phosphorylation and GC. Indeed, histone H1.4S27ph has an anticancer activity,
promoting the stability of the chromatin, and acts as a tumor suppressor in GC lines, controlling growth
and migration. Being human DNA fine regulated by hundreds biological mechanisms, we do believe
that worldwide research needs to proceed several steps forward in understanding how epigenetic
regulation might influence the tumor progression through ERK/MAPKs pathways in GC.
9. miRNAs Regulating MAPK in Gastric Cancer
Micro RNAs (miRNAs), are short non-coding RNAs of approximately 20–22 bp reported to have
a high impact on the regulation of several biological phenomena such as proliferation, migration,
apoptosis, development, angiogenesis, immune response, and cell differentiation [72]. They are
transcribed in the immature form of pri-miRNAs and processed into pre-miRNAs by a nuclear enzyme
complex composed by DGCR8 and Drosha. Pre-miRNAs are then exported from the nucleus into the
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cytosol where they are further processed by the RNAse Dicer. Being the pre-miRNA composed by a -5p
arm, a -3p arm, and a terminal loop, the cut made by Dicer commonly releases two mature miRNAs
which are loaded on the ARGO protein complex, forming the so-called miRNA-induced silencing
complex (miRISC), ready to inhibit the transcription, the translation or the lifetime of many target
mRNAs [73]. Once loaded, ARGO recognizes the -5p arm or the -3p arm as “passenger” and after
releasing the chosen miRNA, this one is degraded, while the other one called “guide” is used to identify
the target mRNA. Having a pleiotropic effect on the regulation of several cellular pathways, miRNAs
play a fundamental role in tumor biology and particularly it was reported that they modulate MAP
kinases, such as Akt, ERK1/2, and JNK, affecting GC cells proliferation, survival, and metastasis [74].
Indeed, being genomic instability one of the main features of many types of advanced GC, it has
been recently proposed a subclassification based on the miRNA profile [75]. Several dysregulated
miRNAs are able to affect the cellular kinase pathways such as miR221/222, which can modulate
PTEN and thus regulate PI3K activity, increasing cell proliferation and survival [76]. miR21 and
miR214 exert the same effect regulating PTEN expression [77]. On the same PI3K-Akt pathway, miR375
targets PDK1, which in turn phosphorylates and thus activates Akt. Thus, overexpression of miR375
inhibits cell viability, leading GC cells to apoptosis [78]. miR375 was reported to target JAK2 as
well, acting as a tumor-suppressor and inhibiting cell proliferation [79]. A more direct approach is
exerted by miR143/145, interacting with Akt itself and so inhibiting proliferation and resistance to
5-fluorouracil [80]. On the other side, miR135b as well, is able to regulate the mammalian ste20-like
kinase 1 (MST1) which in turn decreases the expression of p-p38MAPK, p-ERK1/2, P-glycoprotein,
p38MAPK, ERK1/2, MDR1, MRP1, LRP, and Bcl-2, inhibiting GC cells resistance to cisplatin [81].
miR29 too, may regulate the ERK pathway interfering on the cell cycle [82]. When epigenetically
silenced through hypermethylation, miR181c increased NOTCH2/4 and KRAS expression acting on the
proliferation levels [83]. The study of miRNAs involvement in cancer is not only extremely interesting
from a mere molecular point of view but is also an important topic for the development of future
therapies. Indeed, owing to the more and more fine sequencing techniques, we are increasing the
available knowledge on the mutations of many miRNAs, fueling a personalized medicine approach.
In Table 1 are listed the miRNAs involved in MAPK regulation in GC.
Table 1. A comprehensive list of the most studied miRNAs regulating the MAPK pathways.
miRNA Target Effect Reference
miR21 PTEN Increases cell proliferation and survival [77]
miR29 ERK Inhibits cell proliferation [82]
miR135b MST1 Increases resistance to Cisplatin [81]
miR143/145 Akt Inhibit cell proliferation and 5-FU resistance [80]
miR181c KRAS Inhibits cell proliferation [83]
miR214/221/222 PTEN Increases cell proliferation and survival [76]
miR375 PDK1/JAK2 Inhibits cell proliferation [78,79]
10. lncRNAs Involvement in Gastric Cancer Modulation of MAPK Pathways
Beside microRNAs, another kind of non-coding RNAs are produced in the bulk of transcriptional
output: the long non-coding RNAs (lncRNAs). The lncRNAs are usually RNAs longer than 200 base [84],
but according to St Laurent (2013), it is difficult to standardize the ensemble of the non-coding RNAs
because of “insufficient theoretical basis to classify and categorize the dark matter transcripts” [85].
Nevertheless, many lncRNAs are endowed with regulatory functions and their dysregulation is often
associated to diseases [84]. A recent review [86] illustrates 16 different regulative functions performed
by lncRNAs, from regulation of mRNA decay to sponging and neutralizing miRNAs. Among the
diseases associated to lncRNA dysregulation, there are many degenerative diseases and cancers. In this
panorama GC does not make an exception. Browsing the online lncRNA database at RNACentral
[https://rnacentral.org/] 3474 entries, corresponding to lncRNAs associated to GC, can be retrieved.
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Very often, lncRNAs involved in GC act as a sponge for miRNAs. Some lncRNAs associated to GC are
also responsible for GC overgrowth and survival mediated by the MAPK/ERK pathway. The very first
report about the role of a lncRNA in GC is about antisense H19 [87]. H19 is a non-coding transcript
able to sponge miR675 thus inhibiting the apoptotic process in GC [88]. However, miR675 in colon
cancer has been found to promote migration and invasion via the MAPK signaling pathway [89],
thus it is tempting to speculate that also in GC the MAPK pathway is involved. WT1-AS is another
antisense expressed by the Wilm’s tumor gene [90,91]. The promoter of WT1-AS was found highly
methylated and the antisense transcript downregulated in GC samples with respect to matched normal
mucosa. Also, WT1-AS low expression level correlated with tumor size and clinicopathological stage.
Ectopic expression of WT1-AS resulted in reduction of invasion and proportion of cell in G1 phase
in in vitro experiments and in reduction of tumor growth and metastasis in in vivo experiments.
Authors also demonstrated that WT1-AS overexpression resulted in ERK phosphorylation reduction
and that a MAPK-based mechanism underlie the phenotypic effects. Another study in GC cell lines
demonstrated a role for Yap1 protein, stably elevated in GC specimens, it concurs in promoting GC
growth and metastasis controlling the expression of many lncRNAs and the phosphorylation status
of ERK1/2 [92]. When upregulated Yap1 resulted in elevated ERK1/2 phosphorylation and increased
expression of lncRNAs such as HOTAIR, H19, and MALAT1, respectively. This is the first report of an
association between HOTAIR and MAPK pathway in GC but not the only report about involvement
of HOTAIR in GC. Recently a role for HOTAIR as a miRNA sponge has been described both in GC,
and liver fibrosis [93,94]. In particular HOTAIR acts as a decoy for miR29 and miR618, respectively.
MALAT1 is another lncRNA acting as a sponge for miR124, and in retinoblastoma its overexpression
results in ERK/MAPK and Wnt/β-catenin pathway activation [95]. SNHG6 is also a lncRNA responsible
for JNK regulation in GC [96]. Like other lncRNAs listed above, there are reports suggesting that it
acts as a sponge for miR-101-3P [97], a miRNA associated to the MAPK pathway [98]. lncRNAs is
an emerging and very promising area of focus in GC, and as reported for the miRNAs’ world, recent
sequencing profiling studies have identified several clues of association between such RNAs and
GC. The deeper knowledge of their mutations and effects, will trigger a brand-new era for molecular
biology and will start a new phase of drug development. In Table 2 are listed the lncRNAs involved in
MAPK deregulation in GC.
Table 2. An overall list of lncRNAs modulating the MAPK pathways.
lncRNA Direct Function Effect Reference
HOTAIR miR29 and miR618 sponging [94]
WT1-AS miR-330-5p sponging Downregulated in GC.Inhibits proliferation and invasion [90,99]











CASC2 Unknown Downregulated in GC.Inhibits cell growth [102]
MALAT1 miR124 sponging inretinoblastoma




CARLo-5 Unknown Upregulated in GC. [104]
LINC01138 miR-1273e sponging in GC
Upregulated in GC.
Promotes proliferation, invasion,
migration, and inhibits apoptosis
[105]
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Table 2. Cont.
lncRNA Direct Function Effect Reference
lncNEAT1 miR-129-5p sponging inpapillary thyroid carcinoma










Inhibits proliferation and promote
apoptosis
[109]
MAP3K1-2 Unknown Upregulated in GCPromotes proliferation and invasion [110]
Linc00483 miR-30a-3p sponging
Upregulated in GC
Promotes cell proliferation, invasion and
metastasis
[111]
SLC7A11-AS1 down-modulates sensesequence SLC7A11
Downregulated in GC
Inhibits proliferation in GC [112]
11. Conclusions
MAPKs participate in complex biological systems accounting for an entire world of cellular kinases,
that being activated by many stimuli, in turn influence many important pathways. Their understanding
is of paramount importance, as in numerous cancers the kinases families are commonly dysregulated
and, as reported above, they might be interesting targets for future therapies. GC in particular, showing
several molecular discrepancies among different ethnicities, may be a very interesting model of study
to further understand MAPK roles in cancer. Such discrepancies will need to be further deeply
investigated, not only to select more specific therapeutic protocols, but also to better understand more
thoroughly their molecular bases and effects. We do believe that, even if many findings are slowly
uncovering the real impact of the MAPKs in GC progression and metastasization, much more efforts
need to be spent in order to detect and evaluate all MAPKs regulators and effectors. We hope that
this review article, as a little compendium of the most and recently studied topics about gastric cancer
and MAPKs, will be a stimulus for new researches. Improving the worldwide scientific knowledge
on the involvement of the dysregulated kinase pathways in GC will encourage also new studies
on therapeutic drugs which might improve the survival of GC patients, exploiting such extremely
important cellular kinases.
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